Belite Bio Inc ADR Total Assets
Belite Bio Inc ADR total assets. Based on the latest financial reports, Belite Bio Inc ADR (BLTE) holds total assets worth $791.58 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Belite Bio Inc ADR for the company's overall valuation and market capitalisation.
Total Assets of Belite Bio Inc ADR (2020–2025)
Total assets of Belite Bio Inc ADR from 2020 to 2025. This chart illustrates how Belite Bio Inc ADR's total assets have evolved over time, based on quarterly financial data. See Belite Bio Inc ADR stock price for real-time trading data and today's change.
Belite Bio Inc ADR - Asset Composition Analysis
Belite Bio Inc ADR Total Assets Breakdown (December 2025)
Belite Bio Inc ADR total assets breakdown as of December 2025. Belite Bio Inc ADR's total assets of $791.58 Million consist of 63.3% current assets and 36.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.2% |
| Accounts Receivable | $718.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.92 Million | 0.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Belite Bio Inc ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Belite Bio Inc ADR to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Belite Bio Inc ADR's current assets represent 63.3% of total assets in 2025, a decrease from 99.7% in 2020.
- Cash Position: Cash and equivalents constituted 45.2% of total assets in 2025, down from 99.5% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 0.6% of total assets.
Belite Bio Inc ADR Competitors by Total Assets
Key competitors of Belite Bio Inc ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Belite Bio Inc ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 33.56 | 23.15 | 22.11 |
| Quick Ratio | 33.56 | 23.15 | 22.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $486.65 Million | $144.45 Million | $21.05 Million |
Belite Bio Inc ADR - Advanced Valuation Insights
This section examines the relationship between Belite Bio Inc ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.07 |
| Latest Market Cap to Assets Ratio | 7.90 |
| Asset Growth Rate (YoY) | 413.1% |
| Total Assets | $780.56 Million |
| Market Capitalization | $6.17 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Belite Bio Inc ADR's assets at a significant premium (7.90x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Belite Bio Inc ADR's assets grew by 413.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Belite Bio Inc ADR (2020–2025)
The table below shows the annual total assets of Belite Bio Inc ADR from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $780.56 Million | +413.08% |
| 2024-12-31 | $152.13 Million | +60.74% |
| 2023-12-31 | $94.64 Million | +113.77% |
| 2022-12-31 | $44.27 Million | +141.30% |
| 2021-12-31 | $18.35 Million | -28.72% |
| 2020-12-31 | $25.74 Million | -- |
About Belite Bio Inc ADR
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and … Read more